Spotlight on Infectious Diseases

Credits: 0.25 CME / MOC
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA
Vindico

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Infectious Diseases Presentations

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.25 CME / MOC
Vindico
Complicating Factors in Pediatric Rheumatology: Managing Influenza

Complicating Factors in Pediatric Rheumatology: Managing Influenza

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™/ ABP MOC Part 2
Released: December 31, 2020
Expires: December 30, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
  • Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB


Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi


Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)™/ ABP MOC Part 2
Released: December 31, 2020
Expires: December 30, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
  • Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB


Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi


Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP


Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

1.00 CME / MOC
AKH Inc., Advancing Knowledge in Healthcare
Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Real-World Antimicrobial Data in Clinical Practice: Broadening Coverage at the Bedside: A Clinical Forum℠

Start

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

Activity Details

Free CME/MOC
1.0 AMA PRA Category 1 Credit(s)™/ABIM MOC point(s)
Released: December 30, 2020
Expires: December 29, 2021
60 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

This activity is designed for infectious disease, critical care, and primary care clinicians.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the importance of real-world evidence in clinical decision-making for antimicrobial selection
  • Evaluate real-world data (RWD) as it relates to off-label indications and novel endpoints for gram-positive antimicrobials
  • Apply RWD to ascertain the benefit of antibiotics against a wide spectrum of multidrug-resistant gram-negative bacterial infections

Activity Description

During this activity, Drs. Lodise, Reilly, and Jorgensen present the importance of applying real-world data for antimicrobials in clinical practice. Faculty review highlights from recent real-world evidence and clinical observations for oritavancin, ceftaroline, telavancin, meropenem-vaborbactam, and ceftazidime-avibactam.

Statement of Educational Need

Real-world studies (RWS) are an important means by which data from randomized clinical trials (RCTs) is validated in many different clinical settings. Real-world evidence provides key information on long-term outcomes, efficacy, and safety by gathering prospective or retrospective data from diverse patient populations. RCTs for antimicrobials are limited by strict inclusion and exclusion criteria which lowers patient acuity versus that seen in clinical practice, exclusion of patients at risk for adverse safety outcomes, and challenges in gaining consent from critically ill patients. In addition to evaluating various dosing regimens and providing a wide range of outcomes over time, RWS for antimicrobials include patients who are underrepresented in RCTs and those with resistant infections and higher disease severity. Data obtained from RWS can assist clinicians with therapeutic decision-making for their patients with serious bacterial infections.

Faculty

Chair
Thomas Lodise, PharmD, PhD
Professor
Department of Pharmacy 
Albany College of Pharmacy and Health Services 
Albany, NY 


Joseph Reilly, BS, PharmD, BCGP
Director, Residency Program
Clinical Pharmacist Specialist, Infectious Diseases
AtlantiCare Regional Medical Center
Egg Harbor Township, NJ


Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP
Pharmacotherapy Specialist
Department of Pharmacy
Mount Sinai Hospital
Toronto, ON, Canada


Disclosure Declaration

It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of, or combination of, the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Thomas Lodise, PharmD, PhD, has affiliations with:
Melinta, Merck, Shionogi Inc. (Consultant); Melinta, Shionogi Inc. (Speakers Bureau)

Joseph Reilly, BS, PharmD, BCGP, has affiliations with:
Cumberland, Melinta (Speakers Bureau)

Sarah Jorgensen, PharmD, MPH, BCPS, BCIDP, AAHIVP, has affiliations with:
Sunovion (Speakers Bureau)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations, has no financial relationships to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, Senior Medical Director, has no financial relationships to disclose.
Sharon Powell, Editor, has no financial relationships to disclose.
The RMEI Medical Education planners and managers have nothing to disclose.

Accreditation Statement

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points and 0 patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Statements of credit will be awarded based on the participant reviewing the presentation, scoring a 70% on the post-test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. There is no fee to participant in this activity. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations

This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Melinta Therapeutics, Inc.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.

0.50 CME
Global Education Group
Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Start

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2020
Expires: November 12, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care

Activity Description

This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.

Statement of Educational Need

Depression is common in patients with HIV and can result in nonadherence and reduced levels of viral suppression.1,2 Clinicians should be aware of the relationship between stigma, social isolation, and depression, which may be particularly severe in people of color and men who have sex with men (MSM).3 Pharmacologic treatment of depression can greatly improve quality of life, adherence, and, therefore, viral suppression. Depression is not the only factor that may affect a patient’s mental health. Substance use disorder, or even recreational substance use, which is not uncommon in the HIV population, like depression, may result in reduced adherence or viral suppression.4,5 Patients should be screened in a nonjudgmental manner so that they may be referred to addiction programs or mental health professionals.6 Through a peer-to-peer discussion, Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV specialist can use to screen for and address both mental health disorders and substance use in patients with HIV.
 

  1. Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
  2. Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.  AIDS. 2017;31(18):2515-2524.
  3. Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
  4. Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
  5. Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
  6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.

Faculty

Richard Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Global Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

Trending Clinical Issues Influencing HIV Practice Today: An Online and Mobile Mini-Curriculum—A Practical Approach to Addressing Mental Health in HIV

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: November 12, 2020
Expires: November 12, 2021
30 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, physician assistants, and nurse practitioners involved in the treatment of patients with human immunodeficiency virus (HIV).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Implement screening and appropriate treatment strategies for depression in patients with HIV to optimize adherence and retention in care

Activity Description

This multi-media activity, comprised of slides and graphics with expert audio commentary, is 1 in a series of 4 online, mobile mini-curricula that have been designed to address identified knowledge and practice gaps among infectious disease and HIV specialists, with the overall goal of the program to improve the care of patients with HIV.

Statement of Educational Need

Depression is common in patients with HIV and can result in nonadherence and reduced levels of viral suppression.1,2 Clinicians should be aware of the relationship between stigma, social isolation, and depression, which may be particularly severe in people of color and men who have sex with men (MSM).3 Pharmacologic treatment of depression can greatly improve quality of life, adherence, and, therefore, viral suppression. Depression is not the only factor that may affect a patient’s mental health. Substance use disorder, or even recreational substance use, which is not uncommon in the HIV population, like depression, may result in reduced adherence or viral suppression.4,5 Patients should be screened in a nonjudgmental manner so that they may be referred to addiction programs or mental health professionals.6 Through a peer-to-peer discussion, Dr. Elion and Dr. Treisman provide straightforward strategies that an HIV specialist can use to screen for and address both mental health disorders and substance use in patients with HIV.
 

  1. Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status and association with sustained HIV in care in the United States, 2009-2014. AIDS Behav. 2019;23(12):3452-3459.
  2. Mills JC, Harman JS, Cook RL, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression.  AIDS. 2017;31(18):2515-2524.
  3. Rhodes SD, Hergenrather KC, Vissman AT, et al. Boys must be men, and men must have sex with men: a qualitative CBPR study to explore sexual risk among African American, Latino, and white gay men and MSM. Am J Mens Health. 2011;5(2):140-151.
  4. Bositis CM, St. Louis J. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835-855.
  5. Hartzler B, Dombrowski JC, Williams JR, et al. Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav. 2018;22(3):742-751.
  6. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019; https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. Accessed September 14, 2020.

Faculty

Richard Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia

Glenn Jordan Treisman, MD, PhD
Director, AIDS Psychiatry Service
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Elion, MD: Consultant/Independent Contractor, Speakers Bureau: Gilead Sciences, Inc.; Grant/Research Support, Honoraria: Gilead Sciences, Inc., ViiV Healthcare Limited; Other: Work with Trio Health, who gets grants from Gilead Sciences, Inc. and ViiV Healthcare Limited

Glenn Jordan Treisman, MD, PhD: Nothing to disclose

The following planners and managers reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Gena Dolson, MS, Stacey JP Ullman, MHS, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% on the posttest and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Global Contact Information

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.

0.50 CME
Academy for Continued Healthcare Learning
What Have We Learned? The Neverending Story of COVID-19 and ILD

What Have We Learned? The Neverending Story of COVID-19 and ILD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 10, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
  • Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
  • Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS

Activity Description

What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!

Statement of Educational Need

Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.

Faculty

Tanzira Zaman, MD
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.

Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.

As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.

As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 10, 2021
30 minutes to complete

Accredited By

Target Audience

This activity is intended for pulmonologists, pathologists, radiologists, infectious disease specialists, primary care physicians, and other healthcare providers who care for patients with COVID-19.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the presentation and impact of COVID-19 infection in patients with progressive pulmonary fibrosis
  • Implement strategies to best manage patients with both COVID-19 infection and progressive CF-ILD
  • Incorporate recommendations to appropriately monitor patients with COVID-19-related acute lung injury or ARDS

Activity Description

What have we learned about COVID-19 and interstitial lung disease (ILD)? What do we know now about the potential for fibrosis in those who develop severe COVID-19? This 30-minute “Hot Topics” CME activity, featuring leading pulmonology expert Tanzira Zaman, MD, will break down the key insights as well as the latest trial data and recommendations. This activity will feature text and charts with interspersed short video snippets. Dive into this ever-engaging story and learn more!

Statement of Educational Need

Patients with CF-ILD are, unfortunately, a significantly high-risk group for mortality with COVID-19. Therefore, optimal awareness of both COVID-19 and ILD management is essential. After completing this activity, clinician learners will be better able to evaluate for comorbid COVID-19 infection and ILD, as well as improve the care and management of patients who present with both of these conditions.

Faculty

Tanzira Zaman, MD
Director, Interstitial Lung Disease Program
Associate Program Director, Pulmonary & Critical Care Fellowship
Division of Pulmonary & Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:
Tanzira Zaman, MD
Advisory Panel: United Therapeutics Corporation
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.

Discussion of off-label, Investigational, or Experimental Drug/Device Use: dexamethasone and other treatments not yet approved to treat COVID-19.

As of October 22, 2020, remdesivir is now approved for COVID-19 treatment.

As of November 9, 2020, the FDA has also issued an EUA for bamlanivimab for mild-to-moderate COVID-19 in adult and pediatric patients.

Staff Disclosure

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org

0.75 CME / MOC
Vindico
Managing Influenza in At-Risk Patients to Reduce Infection

Managing Influenza in At-Risk Patients to Reduce Infection

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: December 9, 2020
Expires: December 8, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Implement diagnostic procedures that improve the early detection of influenza in high-risk patients.
  • Differentiate antiviral treatments in terms of efficacy, safety, and their ability to reduce infection and complications in high-risk patients.
  • Incorporate the most appropriate therapeutic regimen in patients with suspected influenza, and who are at high risk for complications.

Activity Description

The majority of influenza hospitalizations and deaths occur in patients at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions. Prevention of infection in patients at high risk for influenza complications is especially critical given the ongoing COVID-19 pandemic. This CME program will deliver the latest data and recommendations regarding timely diagnosis and treatment of influenza so that clinicians are well-equipped to compare the efficacy and safety of available antiviral therapies for influenza prophylaxis and treatment. Using case examples, experts will discuss strategies for incorporating the most appropriate therapeutic regimen to reduce morbidity and mortality in patients who are at high risk for influenza-related complications.

Activity Chair

William A. Fischer II, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute for Global Health and Infectious Diseases
The University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Adjudication Committee: Janssen, Syneos

Faculty

Michael G. Ison, MD, MS, FIDSA, FAST
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL

Disclosure:
Royalty: UpToDate
Consulting Fee: AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
Contracted Research: AiCuris, Genentech/Roche, Janssen, Shire

Andrew T. Pavia, MD, FAAP, FIDSA
George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT

Disclosure:
Royalty: Antimicrobial Therapy, Inc.
Consulting Fee: Genentech, Merck, Seqirus

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)™/
ABIM MOC
Released: December 9, 2020
Expires: December 8, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Implement diagnostic procedures that improve the early detection of influenza in high-risk patients.
  • Differentiate antiviral treatments in terms of efficacy, safety, and their ability to reduce infection and complications in high-risk patients.
  • Incorporate the most appropriate therapeutic regimen in patients with suspected influenza, and who are at high risk for complications.

Activity Description

The majority of influenza hospitalizations and deaths occur in patients at high risk for developing complications, including immunocompromised individuals and those with preexisting respiratory conditions. Prevention of infection in patients at high risk for influenza complications is especially critical given the ongoing COVID-19 pandemic. This CME program will deliver the latest data and recommendations regarding timely diagnosis and treatment of influenza so that clinicians are well-equipped to compare the efficacy and safety of available antiviral therapies for influenza prophylaxis and treatment. Using case examples, experts will discuss strategies for incorporating the most appropriate therapeutic regimen to reduce morbidity and mortality in patients who are at high risk for influenza-related complications.

Activity Chair

William A. Fischer II, MD
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Institute for Global Health and Infectious Diseases
The University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Adjudication Committee: Janssen, Syneos

Faculty

Michael G. Ison, MD, MS, FIDSA, FAST
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Chicago, IL

Disclosure:
Royalty: UpToDate
Consulting Fee: AlloVir, Celltrion, Genentech/Roche, Janssen, Shionogi, Viracor Eurofins
Contracted Research: AiCuris, Genentech/Roche, Janssen, Shire

Andrew T. Pavia, MD, FAAP, FIDSA
George and Esther Gross Presidential Professor
Chief, Division of Pediatric Infectious Diseases
University of Utah
Director, Hospital Epidemiology Program
Primary Children's Hospital
Salt Lake City, UT

Disclosure:
Royalty: Antimicrobial Therapy, Inc.
Consulting Fee: Genentech, Merck, Seqirus

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non—FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Vindico
Influenza in the Hospital: Perils and Pearls
0.75 CME
Vindico
Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Start

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with non-tuberculous mycobacteria (NTM).

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Employ appropriate clinical, imaging, and microbiologic criteria necessary for the diagnosis of NTM.
  • Utilize available evidence-based guidelines to effectively manage NTM pulmonary disease.
  • Incorporate the latest clinical data in the selection of therapy for refractory NTM pulmonary disease.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence.

In this expert panel video, faculty discuss three challenging cases of NTM lung disease. Experts provide guidance on utilization of appropriate diagnostic criteria and discuss evidence-based approaches to manage NTM pulmonary disease. Through case examples, they also review strategies for incorporating the latest clinical data in the selection of therapy for both newly diagnosed and refractory NTM disease.

Activity Chair

Anne E. O'Donnell, MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC

Disclosure:
Consulting Fee: Electromed, Insmed, Merck, Xellia
Contracted Research (Paid to Institution): Insmed

Faculty

David E. Griffith, MD, FACP, FCCP
Overseas Fellow Royal Society of Medicine
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Services Fees: Insmed
Contracted Research: Insmed

Angela DiMango, MD
Associate Professor of Clinical Medicine
Columbia University
Vagelos College of Physicians and Surgeons
New York, New York

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Optimizing Diagnosis and Management of NTM Lung Disease: A Case-Based Expert Panel

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: November 30, 2020
Expires: November 29, 2021
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with non-tuberculous mycobacteria (NTM).

Learning Objectives

Upon successful completion of this activity, participants should be better able to: 

  • Employ appropriate clinical, imaging, and microbiologic criteria necessary for the diagnosis of NTM.
  • Utilize available evidence-based guidelines to effectively manage NTM pulmonary disease.
  • Incorporate the latest clinical data in the selection of therapy for refractory NTM pulmonary disease.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence.

In this expert panel video, faculty discuss three challenging cases of NTM lung disease. Experts provide guidance on utilization of appropriate diagnostic criteria and discuss evidence-based approaches to manage NTM pulmonary disease. Through case examples, they also review strategies for incorporating the latest clinical data in the selection of therapy for both newly diagnosed and refractory NTM disease.

Activity Chair

Anne E. O'Donnell, MD
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Medical Center
Washington, DC

Disclosure:
Consulting Fee: Electromed, Insmed, Merck, Xellia
Contracted Research (Paid to Institution): Insmed

Faculty

David E. Griffith, MD, FACP, FCCP
Overseas Fellow Royal Society of Medicine
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Services Fees: Insmed
Contracted Research: Insmed

Angela DiMango, MD
Associate Professor of Clinical Medicine
Columbia University
Vagelos College of Physicians and Surgeons
New York, New York

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages